• Deutsch
  • Home
  • Search
  • Browse
  • Publish
  • Help
Schließen
  • Faculties
  • Medizinische Fakultät

Theodor-Boveri-Institut für Biowissenschaften

Refine

Has Fulltext

  • yes (276)

Is part of the Bibliography

  • yes (276)

Year of publication

  • 2021 (13)
  • 2020 (8)
  • 2019 (17)
  • 2018 (9)
  • 2017 (9)
  • 2016 (13)
  • 2015 (13)
  • 2014 (20)
  • 2013 (17)
  • 2012 (9)
+ more

Document Type

  • Journal article (205)
  • Doctoral Thesis (50)
  • Book article / Book chapter (9)
  • Conference Proceeding (9)
  • Book (2)
  • Preprint (1)

Language

  • English (235)
  • German (39)
  • Multiple languages (2)

Keywords

  • Physiologische Chemie (45)
  • Schwertkärpfling (19)
  • Melanom (10)
  • melanoma (9)
  • Xiphophorus (8)
  • cancer (7)
  • Signaltransduktion (6)
  • evolution (6)
  • BMP (5)
  • Biochemie (5)
+ more

Author

  • Schartl, Manfred (116)
  • Kneitz, Susanne (21)
  • Linsenmair, Karl Eduard (17)
  • Barnekow, A. (11)
  • Sebald, Walter (11)
  • Wiegering, Armin (11)
  • Anders, F. (10)
  • Eilers, Martin (10)
  • Germer, Christoph-Thomas (10)
  • Epplen, Jörg T. (9)
+ more

Institute

  • Theodor-Boveri-Institut für Biowissenschaften (276)
  • Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (15)
  • Graduate School of Life Sciences (10)
  • Medizinische Klinik und Poliklinik II (8)
  • Pathologisches Institut (8)
  • Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (6)
  • Urologische Klinik und Poliklinik (6)
  • Rudolf-Virchow-Zentrum (5)
  • Klinik und Poliklinik für Strahlentherapie (4)
  • Comprehensive Cancer Center Mainfranken (3)
+ more

Sonstige beteiligte Institutionen

  • Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg, Germany (1)
  • Comprehensive Cancer Centre Mainfranken, University Hospital, University of Wuerzburg, Josef-Schneiderstr. 6, 97080 Wuerzburg, Germany (1)
  • IZKF Laboratory for Microarray Applications, University Hospital of Wuerzburg, Wuerzburg, Germany (1)
  • Microarray Core Unit, Interdisciplinary Center for Clinical Science, University of Würzburg, Versbacher Straße, Würzburg 97080, Germany (1)

EU-Project number / Contract (GA) number

  • 678119 (2)
  • 037220 (1)
  • 222719 (1)
  • 253511 (1)
  • 260464 (1)
  • 602805 (1)
  • 667787 (1)
  • 728018 (1)

276 search hits

  • 1 to 10
  • BibTeX
  • CSV
  • RIS
  • XML
  • 10
  • 20
  • 50
  • 100

Sort by

  • Year
  • Year
  • Title
  • Title
  • Author
  • Author
Brain metastases from colorectal cancer: a systematic review of the literature and meta-analysis to establish a guideline for daily treatment (2021)
Müller, Sophie ; Köhler, Franziska ; Hendricks, Anne ; Kastner, Carolin ; Börner, Kevin ; Diers, Johannes ; Lock, Johan F. ; Petritsch, Bernhard ; Germer, Christoph-Thomas ; Wiegering, Armin
Colorectal cancer (CRC) is the third most common malignancy worldwide. Most patients with metastatic CRC develop liver or lung metastases, while a minority suffer from brain metastases. There is little information available regarding the presentation, treatment, and overall survival of brain metastases (BM) from CRC. This systematic review and meta-analysis includes data collected from three major databases (PubMed, Cochrane, and Embase) based on the key words “brain”, “metastas*”, “tumor”, “colorectal”, “cancer”, and “malignancy”. In total, 1318 articles were identified in the search and 86 studies matched the inclusion criteria. The incidence of BM varied between 0.1% and 11.5%. Most patients developed metastases at other sites prior to developing BM. Lung metastases and KRAS mutations were described as risk factors for additional BM. Patients with BM suffered from various symptoms, but up to 96.8% of BM patients were asymptomatic at the time of BM diagnosis. Median survival time ranged from 2 to 9.6 months, and overall survival (OS) increased up to 41.1 months in patients on a multimodal therapy regimen. Several factors including age, blood levels of carcinoembryonic antigen (CEA), multiple metastases sites, number of brain lesions, and presence of the KRAS mutation were predictors of OS. For BM diagnosis, MRI was considered to be state of the art. Treatment consisted of a combination of surgery, radiation, or systemic treatment.
Cathepsin inhibition modulates metabolism and polarization of tumor-associated macrophages (2020)
Oelschlaegel, Diana ; Weiss Sadan, Tommy ; Salpeter, Seth ; Krug, Sebastian ; Blum, Galia ; Schmitz, Werner ; Schulze, Almut ; Michl, Patrick
Stroma-infiltrating immune cells, such as tumor-associated macrophages (TAM), play an important role in regulating tumor progression and chemoresistance. These effects are mostly conveyed by secreted mediators, among them several cathepsin proteases. In addition, increasing evidence suggests that stroma-infiltrating immune cells are able to induce profound metabolic changes within the tumor microenvironment. In this study, we aimed to characterize the impact of cathepsins in maintaining the TAM phenotype in more detail. For this purpose, we investigated the molecular effects of pharmacological cathepsin inhibition on the viability and polarization of human primary macrophages as well as its metabolic consequences. Pharmacological inhibition of cathepsins B, L, and S using a novel inhibitor, GB111-NH\(_2\), led to changes in cellular recycling processes characterized by an increased expression of autophagy- and lysosome-associated marker genes and reduced adenosine triphosphate (ATP) content. Decreased cathepsin activity in primary macrophages further led to distinct changes in fatty acid metabolites associated with increased expression of key modulators of fatty acid metabolism, such as fatty acid synthase (FASN) and acid ceramidase (ASAH1). The altered fatty acid profile was associated with an increased synthesis of the pro-inflammatory prostaglandin PGE\(_2\), which correlated with the upregulation of numerous NF\(_k\)B-dependent pro-inflammatory mediators, including interleukin-1 (IL-1), interleukin-6 (IL-6), C-C motif chemokine ligand 2 (CCL2), and tumor necrosis factor-alpha (TNFα). Our data indicate a novel link between cathepsin activity and metabolic reprogramming in macrophages, demonstrated by a profound impact on autophagy and fatty acid metabolism, which facilitates a pro-inflammatory micromilieu generally associated with enhanced tumor elimination. These results provide a strong rationale for therapeutic cathepsin inhibition to overcome the tumor-promoting effects of the immune-evasive tumor micromilieu.
Targeting protein synthesis in colorectal cancer (2020)
Schmidt, Stefanie ; Denk, Sarah ; Wiegering, Armin
Under physiological conditions, protein synthesis controls cell growth and survival and is strictly regulated. Deregulation of protein synthesis is a frequent event in cancer. The majority of mutations found in colorectal cancer (CRC), including alterations in the WNT pathway as well as activation of RAS/MAPK and PI3K/AKT and, subsequently, mTOR signaling, lead to deregulation of the translational machinery. Besides mutations in upstream signaling pathways, deregulation of global protein synthesis occurs through additional mechanisms including altered expression or activity of initiation and elongation factors (e.g., eIF4F, eIF2α/eIF2B, eEF2) as well as upregulation of components involved in ribosome biogenesis and factors that control the adaptation of translation in response to stress (e.g., GCN2). Therefore, influencing mechanisms that control mRNA translation may open a therapeutic window for CRC. Over the last decade, several potential therapeutic strategies targeting these alterations have been investigated and have shown promising results in cell lines, intestinal organoids, and mouse models. Despite these encouraging in vitro results, patients have not clinically benefited from those advances so far. In this review, we outline the mechanisms that lead to deregulated mRNA translation in CRC and highlight recent progress that has been made in developing therapeutic strategies that target these mechanisms for tumor therapy.
A duplicated copy of id2b is an unusual sex-determining candidate gene on the Y chromosome of arapaima (Arapaima gigas) (2021)
Adolfi, Mateus C. ; Du, Kang ; Kneitz, Susanne ; Cabau, Cédric ; Zahm, Margot ; Klopp, Christophe ; Feron, Romain ; Paixão, Rômulo V. ; Varela, Eduardo S. ; de Almeida, Fernanda L. ; de Oliveira, Marcos A. ; Nóbrega, Rafael H. ; Lopez-Roques, Céline ; Iampietro, Carole ; Lluch, Jérôme ; Kloas, Werner ; Wuertz, Sven ; Schaefer, Fabian ; Stöck, Matthias ; Guiguen, Yann ; Schartl, Manfred
Arapaima gigas is one of the largest freshwater fish species of high ecological and economic importance. Overfishing and habitat destruction are severe threats to the remaining wild populations. By incorporating a chromosomal Hi-C contact map, we improved the arapaima genome assembly to chromosome-level, revealing an unexpected high degree of chromosome rearrangements during evolution of the bonytongues (Osteoglossiformes). Combining this new assembly with pool-sequencing of male and female genomes, we identified id2bbY, a duplicated copy of the inhibitor of DNA binding 2b (id2b) gene on the Y chromosome as candidate male sex-determining gene. A PCR-test for id2bbY was developed, demonstrating that this gene is a reliable male-specific marker for genotyping. Expression analyses showed that this gene is expressed in juvenile male gonads. Its paralog, id2ba, exhibits a male-biased expression in immature gonads. Transcriptome analyses and protein structure predictions confirm id2bbY as a prime candidate for the master sex-determiner. Acting through the TGF beta signaling pathway, id2bbY from arapaima would provide the first evidence for a link of this family of transcriptional regulators to sex determination. Our study broadens our current understanding about the evolution of sex determination genetic networks and provide a tool for improving arapaima aquaculture for commercial and conservation purposes.
Cysteine restriction in murine L929 fibroblasts as an alternative strategy to methionine restriction in cancer therapy (2021)
Schmitz, Werner ; Ries, Elena ; Koderer, Corinna ; Völter, Maximilian Friedrich ; Wünsch, Anna Chiara ; El-Mesery, Mohamed ; Frackmann, Kyra ; Kübler, Alexander Christian ; Linz, Christian ; Seher, Axel
Methionine restriction (MetR) is an efficient method of amino acid restriction (AR) in cells and organisms that induces low energy metabolism (LEM) similar to caloric restriction (CR). The implementation of MetR as a therapy for cancer or other diseases is not simple since the elimination of a single amino acid in the diet is difficult. However, the in vivo turnover rate of cysteine is usually higher than the rate of intake through food. For this reason, every cell can enzymatically synthesize cysteine from methionine, which enables the use of specific enzymatic inhibitors. In this work, we analysed the potential of cysteine restriction (CysR) in the murine cell line L929. This study determined metabolic fingerprints using mass spectrometry (LC/MS). The profiles were compared with profiles created in an earlier work under MetR. The study was supplemented by proliferation studies using D-amino acid analogues and inhibitors of intracellular cysteine synthesis. CysR showed a proliferation inhibition potential comparable to that of MetR. However, the metabolic footprints differed significantly and showed that CysR does not induce classic LEM at the metabolic level. Nevertheless, CysR offers great potential as an alternative for decisive interventions in general and tumour metabolism at the metabolic level.
Differential expression of transposable elements in the medaka melanoma model (2021)
Helmprobst, Frederik ; Kneitz, Susanne ; Klotz, Barbara ; Naville, Magali ; Dechaud, Corentin ; Volff, Jean-Nicolas ; Schartl, Manfred
Malignant melanoma incidence is rising worldwide. Its treatment in an advanced state is difficult, and the prognosis of this severe disease is still very poor. One major source of these difficulties is the high rate of metastasis and increased genomic instability leading to a high mutation rate and the development of resistance against therapeutic approaches. Here we investigate as one source of genomic instability the contribution of activation of transposable elements (TEs) within the tumor. We used the well-established medaka melanoma model and RNA-sequencing to investigate the differential expression of TEs in wildtype and transgenic fish carrying melanoma. We constructed a medaka-specific TE sequence library and identified TE sequences that were specifically upregulated in tumors. Validation by qRT- PCR confirmed a specific upregulation of a LINE and an LTR element in malignant melanomas of transgenic fish.
Metabolic Fingerprinting of Murine L929 Fibroblasts as a Cell-Based Tumour Suppressor Model System for Methionine Restriction (2021)
Schmitz, Werner ; Koderer, Corinna ; El-Mesery, Mohamed ; Gobik, Sebastian ; Sampers, Rene ; Straub, Anton ; Kübler, Alexander Christian ; Seher, Axel
Since Otto Warburg reported in 1924 that cancer cells address their increased energy requirement through a massive intake of glucose, the cellular energy level has offered a therapeutic anticancer strategy. Methionine restriction (MetR) is one of the most effective approaches for inducing low-energy metabolism (LEM) due to the central position in metabolism of this amino acid. However, no simple in vitro system for the rapid analysis of MetR is currently available, and this study establishes the murine cell line L929 as such a model system. L929 cells react rapidly and efficiently to MetR, and the analysis of more than 150 different metabolites belonging to different classes (amino acids, urea and tricarboxylic acid cycle (TCA) cycles, carbohydrates, etc.) by liquid chromatography/mass spectrometry (LC/MS) defines a metabolic fingerprint and enables the identification of specific metabolites representing normal or MetR conditions. The system facilitates the rapid and efficient testing of potential cancer therapeutic metabolic targets. To date, MS studies of MetR have been performed using organisms and yeast, and the current LC/MS analysis of the intra- and extracellular metabolites in the murine cell line L929 over a period of 5 days thus provides new insights into the effects of MetR at the cellular metabolic level.
Intestinal epithelial barrier maturation by enteric glial cells is GDNF-dependent (2021)
Meir, Michael ; Kannapin, Felix ; Diefenbacher, Markus ; Ghoreishi, Yalda ; Kollmann, Catherine ; Flemming, Sven ; Germer, Christoph-Thomas ; Waschke, Jens ; Leven, Patrick ; Schneider, Reiner ; Wehner, Sven ; Burkard, Natalie ; Schlegel, Nicolas
Enteric glial cells (EGCs) of the enteric nervous system are critically involved in the maintenance of intestinal epithelial barrier function (IEB). The underlying mechanisms remain undefined. Glial cell line-derived neurotrophic factor (GDNF) contributes to IEB maturation and may therefore be the predominant mediator of this process by EGCs. Using GFAP\8^{cre}\) x Ai14\(^{floxed}\) mice to isolate EGCs by Fluorescence-activated cell sorting (FACS), we confirmed that they synthesize GDNF in vivo as well as in primary cultures demonstrating that EGCs are a rich source of GDNF in vivo and in vitro. Co-culture of EGCs with Caco2 cells resulted in IEB maturation which was abrogated when GDNF was either depleted from EGC supernatants, or knocked down in EGCs or when the GDNF receptor RET was blocked. Further, TNFα-induced loss of IEB function in Caco2 cells and in organoids was attenuated by EGC supernatants or by recombinant GDNF. These barrier-protective effects were blunted when using supernatants from GDNF-deficient EGCs or by RET receptor blockade. Together, our data show that EGCs produce GDNF to maintain IEB function in vitro through the RET receptor.
Regeneration of calvarial defects with Escherichia coli-derived rhBMP-2 adsorbed in PLGA membrane (2014)
Ono, Mitsuaki ; Sonoyama, Wataru ; Nema, Kazuki ; Hara, Emilio Satoshi ; Oida, Yasutaka ; Pham, Hai Thanh ; Yamamoto, Katushi ; Hirota, Kazuo ; Sugama, Kazushige ; Sebald, Walter ; Kuboki, Takuo
Objective: Escherichia coli-derived recombinant human bone morphogenetic protein-2 (E-BMP-2) has been shown to be as effective as mammalian cell-derived BMP-2. However, several in vitro and in vivo experiments are still necessary to validate the effectiveness of E-BMP-2 due to the difference in synthesis process, mainly related to protein nonglycosylation. The objective of this study was to investigate whether biodegradable polylactide-co-glycolide (PLGA) membrane is a suitable carrier for E-BMP-2 delivery for bone regeneration of critical-sized defects in rat calvaria. Materials and Methods: First, the osteoinductive effect of E-BMP-2 was confirmed in vitro in mouse bone marrow stromal cells by analysis of osteocalcin mRNA levels, and calcium deposition was detected by alizarin red staining. Before in vivo experiments, the release profile of E-BMP-2 from PLGA membranes was determined by ELISA. E-BMP-2 (0, 1, 5 and 10 μg/μl) was applied for ectopic and orthotopic bone formation and was analyzed by X-ray, micro-CT and histology. Results: Release-profile testing showed that PLGA membrane could retain 94% of the initially applied E-BMP-2. Ectopic bone formation assay revealed that combination of E-BMP-2/PLGA membrane strongly induced bone formation. Stronger osteoinductivity with complete repair of critical-sized defects was observed only with PLGA membranes adsorbed with 5 and 10 μg/μl of E-BMP-2, whereas no bone formation was observed in the groups that received no membrane or 0-μg/μl dose of E-BMP-2. Conclusion: PLGA membrane was shown to be a suitable carrier for sustained release of E-BMP-2, and the E-BMP-2/PLGA membrane combination was demonstrated to be efficient in bone regeneration in a model of critical-sized defects.
Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease (2021)
Hartmann, Oliver ; Reissland, Michaela ; Maier, Carina R. ; Fischer, Thomas ; Prieto-Garcia, Cristian ; Baluapuri, Apoorva ; Schwarz, Jessica ; Schmitz, Werner ; Garrido-Rodriguez, Martin ; Pahor, Nikolett ; Davies, Clare C. ; Bassermann, Florian ; Orian, Amir ; Wolf, Elmar ; Schulze, Almut ; Calzado, Marco A. ; Rosenfeldt, Mathias T. ; Diefenbacher, Markus E.
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients remains low, demonstrating the necessity for novel treatments. One strategy to improve translational research is the development of surrogate models reflecting somatic mutations identified in lung cancer patients as these impact treatment responses. With the advent of CRISPR-mediated genome editing, gene deletion as well as site-directed integration of point mutations enabled us to model human malignancies in more detail than ever before. Here, we report that by using CRISPR/Cas9-mediated targeting of Trp53 and KRas, we recapitulated the classic murine NSCLC model Trp53fl/fl:lsl-KRasG12D/wt. Developing tumors were indistinguishable from Trp53fl/fl:lsl-KRasG12D/wt-derived tumors with regard to morphology, marker expression, and transcriptional profiles. We demonstrate the applicability of CRISPR for tumor modeling in vivo and ameliorating the need to use conventional genetically engineered mouse models. Furthermore, tumor onset was not only achieved in constitutive Cas9 expression but also in wild-type animals via infection of lung epithelial cells with two discrete AAVs encoding different parts of the CRISPR machinery. While conventional mouse models require extensive husbandry to integrate new genetic features allowing for gene targeting, basic molecular methods suffice to inflict the desired genetic alterations in vivo. Utilizing the CRISPR toolbox, in vivo cancer research and modeling is rapidly evolving and enables researchers to swiftly develop new, clinically relevant surrogate models for translational research.
  • 1 to 10

DINI-Zertifikat     OPUS4 Logo

  • Contact
  • |
  • Imprint
  • |
  • Sitemap